Page last updated: 2024-11-04

temozolomide and Carcinogenesis

temozolomide has been researched along with Carcinogenesis in 34 studies

Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.

Research Excerpts

ExcerptRelevanceReference
"Although temozolomide (TMZ) is recommended for glioblastoma (GBM) treatment, patients treated with TMZ usually develop TMZ resistance."8.12Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis. ( Ling, Z; Liu, Q; Zhang, J, 2022)
"It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms."8.12The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022)
"A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)."7.96miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020)
"Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma."7.96MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway. ( Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y, 2020)
"Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma."7.96Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020)
"Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma."7.91MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019)
"Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found."5.51Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration. ( Ahmadi-Zeidabadi, M; Akbarnejad, Z; Eskandary, H; Esmaeeli, M; Masoumi-Ardakani, Y; Mohammadipoor-Ghasemabad, L, 2019)
"Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity."5.48APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance. ( Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M, 2018)
"Although temozolomide (TMZ) is recommended for glioblastoma (GBM) treatment, patients treated with TMZ usually develop TMZ resistance."4.12Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis. ( Ling, Z; Liu, Q; Zhang, J, 2022)
"It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms."4.12The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022)
" The present study evaluates the effects of AT101, alone or in combination with temozolomide (TMZ), in a microenvironmental glioma stem cell niche model of two GBM cell lines (U251MG and U87MG)."4.02Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche. ( Caylioglu, D; Held-Feindt, J; Hellmold, D; Kubelt, C; Meyer, RJ; Synowitz, M, 2021)
"A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)."3.96miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020)
"Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma."3.96MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway. ( Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y, 2020)
"Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma."3.96Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020)
"Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma."3.91MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019)
"Glioblastoma is devastating cancer with a high frequency of occurrence and poor survival rate and it is urgent to discover novel glioblastoma-specific antigens for the therapy."1.56Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells. ( Liu, C; Liu, R; Lu, Y; Zhang, F; Zhang, H, 2020)
"Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found."1.51Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration. ( Ahmadi-Zeidabadi, M; Akbarnejad, Z; Eskandary, H; Esmaeeli, M; Masoumi-Ardakani, Y; Mohammadipoor-Ghasemabad, L, 2019)
" In addition, TMZ could increase the levels of miR-505 and combination with pri-miR-505 and TMZ promoted the suppressive role mediated by miR-505 in GBM cells."1.48Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway. ( Fu, C; Liu, X; Yang, X; Zhang, C, 2018)
"Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity."1.48APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance. ( Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M, 2018)
"Malignant gliomas are a group of aggressive neoplasms among human cancers."1.46Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. ( An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y, 2017)
"Glioma is the most frequent primary central nervous system tumor."1.46β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. ( Chen, FR; Chen, ZP; Feng, HB; Guo, CC; Jiang, HR; Mei, X; Qu, Y; Sai, K; Wang, J; Yang, QY; Zhang, ZP; Zhao, YY, 2017)
"Glioblastoma is the most prevalent primary brain tumor and is essentially universally fatal within 2 years of diagnosis."1.40Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. ( Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P, 2014)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's16 (47.06)24.3611
2020's18 (52.94)2.80

Authors

AuthorsStudies
Li, T1
Mehraein-Ghomi, F1
Forbes, ME1
Namjoshi, SV1
Ballard, EA1
Song, Q1
Chou, PC1
Wang, X7
Parker Kerrigan, BC1
Lang, FF1
Lesser, G1
Debinski, W1
Yang, X4
Zhang, W2
Ling, Z1
Zhang, J4
Liu, Q2
Damanskienė, E1
Balnytė, I1
Valančiūtė, A1
Alonso, MM1
Preikšaitis, A1
Stakišaitis, D1
Elmaci, İ1
Altinoz, MA1
Kahraman Ozlu, EB1
Sari, R1
Er, O1
Gokhan Ekmekci, C1
Turkgenc, B1
Ozpinar, A2
Hacker, E1
Sadeghipour, N1
Kumar, SU1
Massoud, TF1
Paulmurugan, R1
Feng, SW1
Wu, ZS1
Chiu, YL1
Huang, SM1
Aguado, T1
Romero-Revilla, JA1
Granados, R1
Campuzano, S1
Torrente-Rodríguez, RM1
Cuesta, ÁM1
Albiñana, V1
Botella, LM1
Santamaría, S1
Garcia-Sanz, JA1
Pingarrón, JM1
Sánchez-Sancho, F1
Sánchez-Puelles, JM1
Honorato, JR1
Hauser-Davis, RA1
Saggioro, EM1
Correia, FV1
Sales-Junior, SF1
Soares, LOS1
Lima, LDR1
Moura-Neto, V1
Lopes, GPF1
Spohr, TCLS1
Kong, S2
Fang, Y1
Wang, B1
Cao, Y2
He, R1
Zhao, Z2
Li, X11
Li, Z4
Xin, Y1
Meng, Y2
Zhang, F2
Liu, R1
Zhang, H2
Liu, C5
Lu, Y2
Kang, DW1
Hwang, WC1
Noh, YN1
Park, KS1
Min, DS1
Yang, K2
Wei, M1
Yang, Z1
Fu, Z1
Xu, R1
Cheng, C1
Chen, X2
Chen, S3
Dammer, E1
Le, W1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S2
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L3
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G2
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M3
Ma, Q2
Wang, J6
Zhang, E1
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y3
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X2
Ren, Y1
Li, J8
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C4
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Qu, Y2
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J2
Li, M1
Li, W3
Wu, W1
Du, F1
Ji, H1
Xu, Z2
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y3
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z3
Liang, C1
Yang, H1
Song, Y2
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q3
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Gao, F1
Qi, Y1
Lu, H1
Zhang, X6
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y2
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Qi, J2
Mu, J1
Cong, Z1
Fu, D1
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S2
Lin, W1
Zhou, T1
Wu, T1
Wu, Q2
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J2
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Duong, F1
Kong, W1
Chang, JH1
Sun, J2
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B3
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X2
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G2
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P2
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Lu, C1
Zhou, P1
Zhao, L1
Lyu, X1
Yin, J1
Shi, Z1
You, Y1
Mo, L1
Tang, F1
Yan, X1
Yao, X1
Shu, C1
Xiong, J1
Fan, W1
Hu, K1
Yan, Y1
Caylioglu, D1
Meyer, RJ1
Hellmold, D1
Kubelt, C1
Synowitz, M2
Held-Feindt, J2
Kong, Z1
Liu, P1
Ma, W1
Cheng, X1
Fujikawa, A1
Sugawara, H1
Tanaka, T1
Matsumoto, M1
Kuboyama, K1
Suzuki, R1
Tanga, N1
Ogata, A1
Masumura, M1
Noda, M1
Chen, YD1
Dong, TX1
Xu, YT1
An, TT1
Liu, PF1
Yang, XH1
Zhang, C1
Fu, C1
Schmitt, C1
Lucius, R1
Hattermann, K1
Fu, T1
Gao, M1
Hasan, T1
Caragher, SP1
Shireman, JM1
Park, CH1
Atashi, F1
Baisiwala, S1
Lee, G1
Guo, D1
Wang, JY1
Dey, M1
Lesniak, MS1
Horbinski, CM1
James, CD1
Ahmed, AU1
Ahmadi-Zeidabadi, M1
Akbarnejad, Z1
Esmaeeli, M1
Masoumi-Ardakani, Y1
Mohammadipoor-Ghasemabad, L1
Eskandary, H1
Niibori-Nambu, A1
Midorikawa, U1
Mizuguchi, S1
Hide, T1
Nagai, M1
Komohara, Y1
Nagayama, M1
Hirayama, M1
Kobayashi, D1
Tsubota, N1
Takezaki, T1
Makino, K1
Nakamura, H1
Takeya, M1
Kuratsu, J1
Araki, N1
Bai, Y1
Lathia, JD1
Flavahan, W1
Rich, JN1
Mattson, MP1
Hu, Z1
Long, H1
Peng, Y1
Que, T1
Zheng, S1
Wang, G1
Yi, L1
Fang, W1
Qi, S1
Narayan, S1
Sharma, R1
Jiang, P1
Xu, S1
Ma, X1
Zhan, R1
Tsukamoto, Y1
Ohtsu, N1
Echizenya, S1
Otsuguro, S1
Ogura, R1
Natsumeda, M1
Isogawa, M1
Aoki, H1
Ichikawa, S1
Sakaitani, M1
Matsuda, A1
Maenaka, K1
Fujii, Y1
Kondo, T1
Hiddinga, BI1
Pauwels, P1
Janssens, A1
van Meerbeeck, JP1
Feng, HB1
Jiang, HR1
Mei, X1
Zhao, YY1
Chen, FR1
Sai, K1
Guo, CC1
Yang, QY1
Zhang, ZP1
Chen, ZP1

Reviews

4 reviews available for temozolomide and Carcinogenesis

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
    Cells, 2021, 05-10, Volume: 10, Issue:5

    Topics: Animals; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Cancer-Associated Fibroblasts; Carcinogenes

2021
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.
    Life sciences, 2015, Oct-15, Volume: 139

    Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Carc

2015
O
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 107

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung;

2017

Trials

1 trial available for temozolomide and Carcinogenesis

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

30 other studies available for temozolomide and Carcinogenesis

ArticleYear
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2022, 04-06, Volume: 30, Issue:4

    Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat

2022
Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
    Bioengineered, 2022, Volume: 13, Issue:3

    Topics: Apoptosis; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival;

2022
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
    International journal of molecular sciences, 2022, Feb-11, Volume: 23, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, T

2022
MGMT in glial carcinogenesis. Roles from prevention to treatment.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2022, 11-01, Volume: 31, Issue:6

    Topics: Brain Neoplasms; Carcinogenesis; Carcinogens; Dacarbazine; DNA; DNA Methylation; DNA Modification Me

2022
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.
    Scientific reports, 2022, 07-14, Volume: 12, Issue:1

    Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi

2022
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
    International journal of molecular sciences, 2023, May-25, Volume: 24, Issue:11

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr

2023
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
    Scientific reports, 2019, 08-15, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Carcinogenesis; Cell Line, Tumor; Cell Prolif

2019
Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma.
    Journal of cellular physiology, 2020, Volume: 235, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Beclin-1; Carcinogenesis; Cell Cycle; Cell Li

2020
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:8

    Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug

2020
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:8

    Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistan

2020
Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
    BMC cancer, 2020, Jul-18, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Ce

2020
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
    The Journal of pathology, 2020, Volume: 252, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carcinogenesis; Cell

2020
Activation of dopamine receptor D1 inhibits glioblastoma tumorigenicity by regulating autophagic activity.
    Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6

    Topics: Animals; Autophagy; Calcium; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Hum

2020
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.
    Neuro-oncology, 2021, 04-12, Volume: 23, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Prolif

2021
RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
    Cell death & disease, 2020, 10-22, Volume: 11, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Carcinogenesis; Cell Line, Tumo

2020
The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma.
    Aging, 2021, 02-17, Volume: 13, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclin-Depende

2021
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
    International journal of molecular sciences, 2021, Mar-30, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T

2021
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
    Scientific reports, 2017, 07-17, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Enzyme Inhibitors; Female; Glioblastoma;

2017
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
    Molecular medicine reports, 2017, Volume: 16, Issue:6

    Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi

2017
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
    Gene, 2018, Sep-25, Volume: 672

    Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neopla

2018
APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
    Oncology reports, 2018, Volume: 40, Issue:5

    Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Drug Re

2018
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
    European journal of pharmacology, 2019, Jun-05, Volume: 852

    Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease

2019
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
    Cell death & disease, 2019, 03-29, Volume: 10, Issue:4

    Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla

2019
Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.
    Electromagnetic biology and medicine, 2019, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Calcium; Carcinogenesis; Cell Differentiation; Cell Line, Tumor; C

2019
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S

2013
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
    Glia, 2014, Volume: 62, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; C

2014
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
    Journal of neuro-oncology, 2014, Volume: 119, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C

2014
Suppressing H19 Modulates Tumorigenicity and Stemness in U251 and U87MG Glioma Cells.
    Cellular and molecular neurobiology, 2016, Volume: 36, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; C

2016
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
    Stem cells (Dayton, Ohio), 2016, Volume: 34, Issue:8

    Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell

2016
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
    Stem cells translational medicine, 2017, Volume: 6, Issue:3

    Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati

2017